MOSL: EXPERT SPEAK-US generics in recovery mode; Better prospects in Emerging Markets as well

EXPERT SPEAK: US generics in recovery mode; Better prospects in Emerging Markets as well

Mr. Abhijit Mukherjee, ex-COO, Dr. Reddy’s Laboratories

He is a rare combination —seasoned marketing and sales acumen, with rich technical knowledge, supporting him in shouldering the responsibility of manufacturing, sales and marketing of DRRD products across 19 countries, with focus on the US, India, and Russia.

He played a key role in strategic initiatives of the company; like acquisition of ROCHE API business at Mexico and alliance with GSK for emerging markets. A chemical engineer from IIT Kharagpur, Mr. Mukherjee joined DRRD in 2003, bringing with him vast experience in strong marketing-focused companies like Unilever and reputed specialty chemical companies.

• We met Mr. Abhijit Mukherjee, the ex-COO of Dr. Reddy's Laboratories (DRRD), who retired on 31 March 2018. Currently, Mr. Mukherjee is an advisor to some pharma companies, sharing his knowledge on strategic and operational matters. Key takeaways from the meeting:
• The US generics market is in a recovery phase with limited downside in its existing business for companies with a diversified base. Incremental growth is expected from a healthy pipeline of differentiated products.
• The attractive valuation of recent deals should lead to more consolidation opportunities.
• Other than the US, emerging markets look promising with stability in the eco-political situation and its relative currency movement, thereby aiding better growth in business prospects from these regions.
• In order to curb healthcare cost, Government intervention on price capping may continue.
• The China pharmaceutical market offers strong business prospects to Indian pharmaceutical companies, choosing the right products and a good quality dossier.